| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1081/CNV-200027148 |
| P698 | PubMed publication ID | 15565818 |
| P2093 | author name string | William A Denny | |
| P2860 | cites work | Hypoxia--a key regulatory factor in tumour growth | Q29547318 |
| A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation | Q31367858 | ||
| In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation | Q31925983 | ||
| Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). | Q33343994 | ||
| Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase | Q33630320 | ||
| Cytochrome P450-based cancer gene therapy: recent advances and future prospects | Q33639790 | ||
| Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs | Q33746856 | ||
| In situ use of suicide genes for therapy of brain tumours | Q33841658 | ||
| Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study | Q33863802 | ||
| Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development | Q33956983 | ||
| Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives | Q34176439 | ||
| Eradication of large colon tumor xenografts by targeted delivery of maytansinoids | Q34389426 | ||
| Prodrug strategies in cancer therapy | Q34400910 | ||
| Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy | Q34819107 | ||
| Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase | Q35693935 | ||
| Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9 | Q36431639 | ||
| Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin | Q36618010 | ||
| Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent | Q36621020 | ||
| Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine | Q36621361 | ||
| Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry | Q36872080 | ||
| Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate | Q40820608 | ||
| Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). | Q40848113 | ||
| Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group | Q40931017 | ||
| Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase | Q41004810 | ||
| DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides | Q41140887 | ||
| Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. | Q41218087 | ||
| Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase | Q41308216 | ||
| Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species | Q41661399 | ||
| The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity | Q41735615 | ||
| Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT) | Q42287196 | ||
| Targeting enzymes for cancer therapy: old enzymes in new roles | Q42590388 | ||
| The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). | Q42606499 | ||
| Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck | Q44740191 | ||
| A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
| Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression | Q45863437 | ||
| Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment | Q45881620 | ||
| Preparation and characterization of a .beta.-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents | Q45940039 | ||
| Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. | Q50497363 | ||
| Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. | Q50506494 | ||
| Hypoxic regions exist in human prostate carcinoma. | Q51481357 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 604-619 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Cancer Investigation | Q325953 |
| P1476 | title | Tumor-activated prodrugs--a new approach to cancer therapy | |
| P478 | volume | 22 |
| Q34044370 | A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy |
| Q35556939 | A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy |
| Q36373103 | Antibody targeted drugs as cancer therapeutics |
| Q39914185 | Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy |
| Q48986853 | Conditional Toxin Splicing Using a Split Intein System |
| Q39028860 | Conditional protein splicing of α-sarcin in live cells |
| Q36490753 | Development of antibodies and chimeric molecules for cancer immunotherapy |
| Q40016903 | Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT. |
| Q39965327 | E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2. |
| Q33839227 | Enzymatic activation of a matrix metalloproteinase inhibitor |
| Q55252030 | Enzymatically promoted release of organic molecules linked to magnetic nanoparticles. |
| Q43737005 | Enzyme-responsive snap-top covered silica nanocontainers |
| Q35234948 | Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. |
| Q33946444 | Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue |
| Q37318264 | Ferrous iron-dependent drug delivery enables controlled and selective release of therapeutic agents in vivo |
| Q35661899 | Genetic control of wayward pluripotent stem cells and their progeny after transplantation |
| Q46919790 | Hydrogen peroxide overproduced in breast cancer cells can serve as an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under the effect of tamoxifen-ferrocene conjugate |
| Q39002822 | Hypoxia: A Double-Edged Sword in Cancer Therapy |
| Q36150524 | Immunotherapy and immunoprevention of cancer: where do we stand? |
| Q40183772 | Inhibitory effect of pulmonary carcinoma by adenovirus-mediated CD/UPRT gene |
| Q35005290 | Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. |
| Q34912725 | Integrin targeted delivery of chemotherapeutics |
| Q53689115 | Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment. |
| Q38413737 | Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges. |
| Q33812832 | Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue |
| Q36360811 | Metabolism and transport of oxazaphosphorines and the clinical implications |
| Q36274391 | Modulation of cytochrome P450 activity: implications for cancer therapy |
| Q36739759 | Monoclonal antibody-based therapeutics for leukemia |
| Q37836419 | On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds |
| Q90038480 | Optimized Scintillator YAG:Pr Nanoparticles for X-ray Inducible Photodynamic Therapy |
| Q37487102 | Peptide modified mesoporous silica nanocontainers. |
| Q39229406 | Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy |
| Q37150860 | Prodrug approaches for CNS delivery |
| Q33490199 | Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries |
| Q39140632 | Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy |
| Q36318531 | Recent advances in targeted therapy of human myelogenous leukaemia |
| Q38702949 | Recent updates in utilizing prodrugs in drug delivery (2013-2015). |
| Q38533459 | Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma |
| Q37353096 | Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery |
| Q34480712 | Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs. |
| Q38191293 | Targeting kallikrein-related peptidases in prostate cancer |
| Q50987490 | The two faces of potent antitumor duocarmycin-based drugs: a structural dissection reveals disparate motifs for DNA versus aldehyde dehydrogenase 1 affinity. |
| Q34217778 | The use of neural stem cells in cancer gene therapy: predicting the path to the clinic |
| Q33272567 | Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells |
| Q37174938 | Use of antibodies and immunoconjugates for the therapy of more accessible cancers |
Search more.